Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 202
Appendix B Workshop Agenda Improving the Translation of Research Findings into Clinical Practice: I. The Potential and Problems of Modern Methods of Clinical Investigation Wednesday, May 3, 1989 8:00 a.m. 8:30 a.m. Session One: Registration and Continental Breakfast Welcome and Opening Remarks Samuel Thier, President, Institute of Medicine Gerald Laubach, Chair, Committee on Technological Innovation in Medicine Setting the Stage Keynote Address 8:45 a.m. Technological Innovation and Evaluation in Medicine Samuel Thier, Institute of Medicine Session Two: Outcomes and Evaluative Research Moderator: Paul Parkman, Food and Drug Administration 202
OCR for page 203
APPENDIX B 9:15 a.m. The Selection of Endpoints in Evaluative Research John Bunker, Stanford University 9:45 a.m. 203 Advances in Health Status Measurement: The Potential to Improve Experimental and Non-Experimental Data Collection Marilyn Bergner, Johns Hopkins University 10:15 a.m. General Discussion 10:45 a.m. Break Session Three: Modern Epidemiologic Methods for Obtaining Primary Evidence Moderator: Paul Stolley, University of Pennsylvania 11:00 a.m. What Is Outcomes Research? John Wennberg, Dartmouth College 11:45 a.m. Strengths and Weaknesses of Health Insurance Data Systems for Assessing Outcomes Leslie Roos and Noralou Roos, University of Manitoba, Canada 12:15 p.m. General Discussion 1:00 p.m. 2:00 p.m. Lunch Prescription-Event Monitoring: An Example of Total Population Post-Marketing Drug Surveillance William Unman, Drug Safety Research Unit, United Kingdom Discussant: Brian Strom, University of Pennsylvania 2:30 p.m. General Discussion Session Four: Modern Methods to Synthesize Existing Evidence Moderator: Frederick Mosteller, Harvard University 3:00 p.m. The Value of Modern Methods of Decision Analysis Albert Mulley, Massachusetts General Hospital
OCR for page 204
204 3:30 p.m. 4:00 p.m. 4:30 p.m. 5:30 p.m. 6:15 p.m. Thursday, May 4, 1989 APPENDIX B The Value of Modern Methods of Meta-Analysis Stephen Thacker, Center for Environmental Health and Injury Control, Centers for Disease Control A Bayesian Approach to Clinical Evaluation David Eddy, Duke University General Discussion Adjourn and Reception Dinner 8:30 a.m. Continental Breakfast Session Five: Modern Methods of Clinical Evaluation: What Are the Challenges and Consequences for Technological Innovation in Medicine? Keynote Address 9:15 a.m. Can We Improve the Transfer of Research Findings Into Clinical Practice Through Modern Methods of Evaluation? David Eddy, Duke University 10:00 a.m. 10:15 a.m. 11:45 a.m. 12:45 p.m. Break Roundtable Discussion (A) Moderator: Harvey Fineberg, Harvard University Panel Members: David Eddy, Duke University Alvan Feinstein, Yale University Robert Levy, Sandoz Research Institute Robert Temple, Food and Drug Administration Salim Yusuf, National Heart, Lung, and Blood Institute Lunch Factors That Influence the Utilization of Modern Evaluative Methods Kenneth Melmon, Stanford University
OCR for page 205
APPENDIX B 1:30 p.m. 3:00 p.m. 3:15 p.m. 205 Roundtable Discussion (1~) Moderator: Charles Sanders, Squibb Panel Members: Susan Bartlett Foote, University of California, Berkeley Jere Goyan, University of California, San Francisco Ben Holmes, Hewlett-Packard William Hubbard, Council on Health Care Technology, Institute of Medicine Kenneth Melmon, Stanford University Stephen Sherwin, Genentech M. Roy Schwarz, American Medical Association Summary of the Meeting Gerald Laubach, Chair, Committee on Technological Innovation in Medicine Adjourn
Representative terms from entire chapter: